drugset / Trial / NCT03718039

Phase 2 Bunionectomy HTX-011 Administration Study

NCT03718039

Phase 2 Completed 78 enrolled Heron Therapeutics
Non-randomizedSingle-groupOpen-labelPrevention

Summary

This is a Phase 2, open-label, multi-cohort study to evaluate the analgesic efficacy, safety, and pharmacokinetics (PK) of a single, individualized dose of HTX-011 administered into the surgical site as a monotherapy or with other medications to enhance analgesia in subjects undergoing unilateral simple bunionectomy.

Timeline

Start
2018-10-24
Primary completion
2019-01-31
Completion
2019-03-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Aprepitant Other / unclassified Oral
Subject HTX-011 Unknown Other

Indications

No indication recorded.